ArticleGene therapy2011
Delivery of gelfoam-enabled cells and vectors into the pericardial space using a percutaneous approach in a porcine model.
Article in Gene therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 61 citations in OpenAlex.
- Intrapericardially injected hydrogel loaded with stromal cell secretome microparticles improves post-infarction myocardial repair in pigs.European heart journal · 2026Article
- Intravascularly Deliverable Biomaterial Platforms for Tissue Repair and Regeneration Post-Myocardial Infarction.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- An infusible biologically active adhesive for chemotherapy-related heart failure in elderly rats.Bioactive materials · 2024Article
- Current Landscape of Gene Therapy for the Treatment of Cardiovascular Disorders.Current gene therapy · 2024Review
- Micronized Acellular Matrix Biomaterial Leverages Eosinophils for Postinfarct Cardiac Repair.JACC. Basic to translational science · 2023Article
- Enhancing the Effect of Placental Extract on the Regeneration of Crush Injured Facial Nerve.Experimental neurobiology · 2022Article
- Small non-coding RNA therapeutics for cardiovascular disease.European heart journal · 2022Review
- Emerging Polymer Materials in Trackable Endovascular Embolization and Cell Delivery: From Hype to Hope.Biomimetics (Basel, Switzerland) · 2022Review
- The epicardial delivery of cardiosphere derived cells or their extracellular vesicles is safe but of limited value in experimental infarction.Scientific reports · 2021Article
- Targeted delivery of therapeutic agents to the heart.Nature reviews. Cardiology · 2021Review
- All Roads Lead to Rome (the Heart): Cell Retention and Outcomes From Various Delivery Routes of Cell Therapy Products to the Heart.Journal of the American Heart Association · 2021Review
- Minimally invasive delivery of therapeutic agents by hydrogel injection into the pericardial cavity for cardiac repair.Nature communications · 2021Article
- Immune-modulatory alginate protects mesenchymal stem cells for sustained delivery of reparative factors to ischemic myocardium.Biomaterials science · 2020Article
- Pericardial Delivery of Biological Agents: The Next Frontier?JACC. Basic to translational science · 2017Article
- Article
- Design of Injectable Materials to Improve Stem Cell Transplantation.Current stem cell reports · 2016Article
- Intrapericardial Delivery of Cardiosphere-Derived Cells: An Immunological Study in a Clinically Relevant Large Animal Model.PloS one · 2016Article
- Intrapericardial administration of mesenchymal stem cells in a large animal model: a bio-distribution analysis.PloS one · 2015Article
- Concise review: injectable biomaterials for the treatment of myocardial infarction and peripheral artery disease: translational challenges and progress.Stem cells translational medicine · 2014Review
- Fused X-ray and MR imaging guidance of intrapericardial delivery of microencapsulated human mesenchymal stem cells in immunocompetent swine.Radiology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
Intrapericardial drug delivery is a promising procedure, with the ability to localize therapeutics with the heart. Gelfoam particles are nontoxic, inexpensive, nonimmunogenic and biodegradable compounds that can be used to deliver therapeutic agents. We developed a new percutaneous approach method for intrapericardial injection, puncturing the pericardial sac safely under fluoroscopy and intravascular ultrasound (IVUS) guidance. In a porcine model of myocardial infarction (MI), we deployed gelfoam particles carrying either (a) autologous mesenchymal stem cells (MSCs) or (b) an adenovirus encoding enhanced green fluorescent protein (eGFP) 48 h post-MI. The presence of MSCs and viral infection at the infarct zone was confirmed by immunoflourescence and PCR. Puncture was performed successfully in 16 animals. Using IVUS, we successfully determined the size of the pericardial space before the puncture, and safely accessed that space in setting of pericardial effusion and also adhesions induced by the MI. Intrapericardial injection of gelfoam was safe and reliable. Presence of the MSCs and eGFP expression from adenovirus in the myocardium were confirmed after delivery. Our novel percutaneous approach to deliver (stem-) cells or adenovirus was safe and efficient in this pre-clinical model. IVUS-guided delivery is a minimally invasive procedure that seems to be a promising new strategy to deliver therapeutic agents locally to the heart.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.